Systemic lupus erythematosus (SLE) is a complex, prototypic, systemic autoimmune disease of great interest to the Autoimmunity Center of Excellence network. However, by the time patients receive the devastating SLE diagnosis, the majority have ongoing aggressive inflammatory processes and oftentimes damage that cannot be reversed. Once these autoimmune cascades are underway, dissecting the basic concepts of disease initiation, perpetuation and direct pathogenesis from the complications of end-organ damage can be quite difficult. Our Oklahoma ACE builds on unique populations and experimental systems to address early events in systemic autoimmunity. Few repositories exist that allow researchers to investigate SLE development before clinical manifestations. Through our collaboration with the US Department of Defense, we have identified 240 patients who developed SLE while serving in the US military and who had serum samples that were provided before SLE classification. We previously obtained serial samples from the DoDSR for 130 of these patients, as well as four matched controls for each patient. Initial studies with these samples found that autoantibodies precede clinical illness by many years, that the Sm and Ro (alone) systems begin by targeting a single antigenic structure then become progressively more complicated and that a few autoantibodies are detectable before their associated clinical manifestations. In addition, we now have in house the samples from an additional 100 SLE patients and their matched controls and are seeking ACE funding to examine temporal associations of key targetable pathways in the pre-clinical stages to support or refute rationale use of interventions directed against interferon alpha or vitamin D supplementation for SLE patients. Further elucidation of the etiology and early pathogenesis of SLE will also provide improved biomarkers regarding select aspects of autoantibodies that correlate with onset of clinical disease features, and identify autoantibody subsets that help predict disease and allow identification of "high risk" populations for potential interventional trials.
Our specific aims will address the following key clinical questions: 1) Does vitamin D deficiency precede lupus autoimmunity and/or clinical disease onset? 2) Does an increase in interferon activity occur before or concurrently with the onset of lupus autoimmunity or clinical disease? 3) Does non-specific autoimmunity precede onset of lupus-specific autoimmunity and thereby serve as a predictor of disease? 4) Does autoantibody concentration, specificity or affinity change with symptom onset and can these changes help direct therapeutic decisions?

Public Health Relevance

Understanding the initial targets and pre-clinical features of SLE will provide the basis for the development of lupus-specific diagnostic tests, evaluation of candidate pathways to target for SLE therapies, assessment of temporal associations to examine surrogates of causation for select biomarkers, and the determination of patients with the highest likelihood of response to specific therapies and for recruitment to potential prevention trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082714-05
Application #
8461113
Study Section
Special Emphasis Panel (ZAI1-QV-I)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$256,511
Indirect Cost
$82,577
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Morris, D L; Fernando, M M A; Taylor, K E et al. (2014) MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun 15:210-7
Rasmussen, Astrid; Ice, John A; Li, He et al. (2014) Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 73:31-8
Ritterhouse, Lauren L; Lu, Rufei; Shah, Hemangi B et al. (2014) Vitamin d deficiency in a multiethnic healthy control cohort and altered immune response in vitamin D deficient European-American healthy controls. PLoS One 9:e94500
Young, K A; Terrell, D R; Guthridge, J M et al. (2014) Smoking is not associated with autoantibody production in systemic lupus erythematosus patients, unaffected first-degree relatives, nor healthy controls. Lupus 23:360-9
Guthridge, Joel M; Lu, Rufei; Sun, Harry et al. (2014) Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am J Hum Genet 94:586-98
Munroe, Melissa E; Vista, Evan S; Guthridge, Joel M et al. (2014) Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol 66:1888-99
James, Judith A (2014) Clinical perspectives on lupus genetics: advances and opportunities. Rheum Dis Clin North Am 40:413-32, vii
Kim-Howard, Xana; Sun, Celi; Molineros, Julio E et al. (2014) Allelic heterogeneity in NCF2 associated with systemic lupus erythematosus (SLE) susceptibility across four ethnic populations. Hum Mol Genet 23:1656-68
Sakurai, Daisuke; Zhao, Jian; Deng, Yun et al. (2013) Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression. PLoS Genet 9:e1003870
Manku, Harinder; Langefeld, Carl D; Guerra, Sandra G et al. (2013) Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4. PLoS Genet 9:e1003554

Showing the most recent 10 out of 48 publications